The specter of zoonotic spillover from animal coronaviruses continues to pose pandemic risks, making the development of broad-spectrum antiviral tools increasingly urgent. Recent spillovers of porcine deltacoronavirus into human populations in Haiti underscore how quickly animal pathogens can cross species barriers, yet no approved therapeutics exist for this emerging threat. Researchers have now engineered a synthetic miniprotein called MB11 using computational design methods, demonstrating potent inhibitory activity against deltacoronavirus infection. The miniprotein was created through iterative computational modeling to optimize binding affinity to the viral spike protein, representing a new class of engineered biological therapeutics. Unlike traditional drug discovery approaches that screen existing compounds, this computational design strategy builds novel protein scaffolds from first principles to target specific viral vulnerabilities. The MB11 miniprotein showed exceptional binding strength and neutralization capacity in laboratory studies, suggesting computational protein design could accelerate development of countermeasures against emerging coronaviruses. This approach offers several advantages over conventional antiviral development: miniproteins are typically more stable than antibodies, can be produced cost-effectively in bacterial systems, and their small size may improve tissue penetration. However, significant hurdles remain before clinical application. The deltacoronavirus family remains understudied compared to alpha and beta coronaviruses, limiting our understanding of resistance mechanisms and cross-strain efficacy. Animal studies and human safety trials would be essential next steps. While promising as a proof-of-concept for computational antiviral design, the work primarily demonstrates technical feasibility rather than immediate therapeutic readiness for pandemic preparedness.